Patent SG-11201907840R-A (SG)
Title: Fused imidazo-piperidine jak inhibitors
Inventor: FATHEREE PAUL R
IPC: A61K31/437
Filed: 2018-03-08
Abstract: HNN N (I) W O 18/ 165 395 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIP0 I PCT oimiolo VIII °nolo VIII 011101110111 H imio oimIE (10) International Publication Number WO 2018/165395 Al (51) International Patent Classification: CO7D 471/04 (2006.01) A61K 31/437 (2006.01) A61P 11/00 (2006.01) (21) International Application Number: PCT/US2018/021492 (22) International Filing Date: 08 March 2018 (08.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/469,073 09 March 2017 (09.03.2017) US (71) Applicant: THERAVANCE BIOPHARMA R&D IP, LLC [US/US]; 901 Gateway Boulevard, South San Fran- cisco, California 94080 (US). (72) Inventors: FATHEREE, Paul R.; 921 Minnesota Street, San Francisco, California 94107 (US). BRANDT, Gary E.L.; 2160 Buena Vista Avenue, Alameda, California 94501 (US). SMITH, Cameron; 4256 Shelter Creek Lane, San Bruno, California 94066 (US). SULLIVAN, Steven D.E.; 1417 17th Avenue, San Francisco, California 94122 (US). VAN ORDEN, Lori Jean; 3 Whitney Street, San Francisco, California 94131 (US). KLEINSCHEK, Melanie A.; 30 Elizabeth Street, San Francisco, California 94110 (US). CRATER, Glenn D.; 7108 Rippling Stone Ln, Raleigh, North Carolina 27612 (US). (74) Agent: HAGENAH, Jeffrey A. et al.; Theravance Biophar- ma US, Inc., 901 Gateway Boulevard, South San Francisco, California 94080 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: FUSED IMIDAZO-PIPERIDINE JAK INHIBITORS (57) : The invention provides compounds of formula (I): (I) where the vari- ables are defined in the specification, or a pharmaceutically-acceptable salt thereof, HO that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such com- pounds.